Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. (CRXT) Stock Competitors & Peer Comparison
See (CRXT) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CRXT | $0.05 | -31.16% | 0 | -0.02 | -$2.80 | N/A |
| LLY | $1,023.22 | +0.00% | 952.9B | 43.99 | $22.96 | +0.62% |
| AZN | $208.62 | +1.05% | 633.8B | 31.30 | $6.53 | +1.82% |
| JNJ | $246.91 | +0.00% | 584.4B | 22.01 | $11.02 | +2.10% |
| ABBV | $224.35 | +0.00% | 397.6B | 95.32 | $2.36 | +2.94% |
| NVS | $163.92 | +0.00% | 314.5B | 22.78 | $7.14 | +2.01% |
| MRK | $121.86 | +0.00% | 305.4B | 16.80 | $7.28 | +2.68% |
| NVO | $48.45 | +0.00% | 210.9B | 12.96 | $3.66 | +2.59% |
| AMGN | $375.50 | +0.00% | 202B | 26.34 | $14.23 | +2.58% |
| GILD | $151.12 | +0.00% | 187.8B | 18.58 | $8.15 | +2.09% |
Stock Comparison
CRXT vs LLY Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, LLY has a market cap of 952.9B. Regarding current trading prices, CRXT is priced at $0.05, while LLY trades at $1,023.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas LLY's P/E ratio is 43.99. In terms of profitability, CRXT's ROE is -4.63%, compared to LLY's ROE of +0.98%. Regarding short-term risk, CRXT is more volatile compared to LLY. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check LLY's competition here
CRXT vs AZN Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, AZN has a market cap of 633.8B. Regarding current trading prices, CRXT is priced at $0.05, while AZN trades at $208.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas AZN's P/E ratio is 31.30. In terms of profitability, CRXT's ROE is -4.63%, compared to AZN's ROE of +0.23%. Regarding short-term risk, CRXT is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check AZN's competition here
CRXT vs JNJ Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, JNJ has a market cap of 584.4B. Regarding current trading prices, CRXT is priced at $0.05, while JNJ trades at $246.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas JNJ's P/E ratio is 22.01. In terms of profitability, CRXT's ROE is -4.63%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, CRXT is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check JNJ's competition here
CRXT vs ABBV Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, ABBV has a market cap of 397.6B. Regarding current trading prices, CRXT is priced at $0.05, while ABBV trades at $224.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas ABBV's P/E ratio is 95.32. In terms of profitability, CRXT's ROE is -4.63%, compared to ABBV's ROE of -4.22%. Regarding short-term risk, CRXT is more volatile compared to ABBV. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check ABBV's competition here
CRXT vs NVS Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, NVS has a market cap of 314.5B. Regarding current trading prices, CRXT is priced at $0.05, while NVS trades at $163.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas NVS's P/E ratio is 22.78. In terms of profitability, CRXT's ROE is -4.63%, compared to NVS's ROE of +0.33%. Regarding short-term risk, CRXT is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check NVS's competition here
CRXT vs MRK Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, MRK has a market cap of 305.4B. Regarding current trading prices, CRXT is priced at $0.05, while MRK trades at $121.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas MRK's P/E ratio is 16.80. In terms of profitability, CRXT's ROE is -4.63%, compared to MRK's ROE of +0.36%. Regarding short-term risk, CRXT is more volatile compared to MRK. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check MRK's competition here
CRXT vs NVO Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, NVO has a market cap of 210.9B. Regarding current trading prices, CRXT is priced at $0.05, while NVO trades at $48.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas NVO's P/E ratio is 12.96. In terms of profitability, CRXT's ROE is -4.63%, compared to NVO's ROE of +0.61%. Regarding short-term risk, CRXT is more volatile compared to NVO. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check NVO's competition here
CRXT vs AMGN Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, AMGN has a market cap of 202B. Regarding current trading prices, CRXT is priced at $0.05, while AMGN trades at $375.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas AMGN's P/E ratio is 26.34. In terms of profitability, CRXT's ROE is -4.63%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, CRXT is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check AMGN's competition here
CRXT vs GILD Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, GILD has a market cap of 187.8B. Regarding current trading prices, CRXT is priced at $0.05, while GILD trades at $151.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas GILD's P/E ratio is 18.58. In terms of profitability, CRXT's ROE is -4.63%, compared to GILD's ROE of +0.41%. Regarding short-term risk, CRXT is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check GILD's competition here
CRXT vs PFE Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, PFE has a market cap of 151.6B. Regarding current trading prices, CRXT is priced at $0.05, while PFE trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas PFE's P/E ratio is 19.60. In terms of profitability, CRXT's ROE is -4.63%, compared to PFE's ROE of +0.09%. Regarding short-term risk, CRXT is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check PFE's competition here
CRXT vs BMY Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, BMY has a market cap of 123.6B. Regarding current trading prices, CRXT is priced at $0.05, while BMY trades at $60.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas BMY's P/E ratio is 17.54. In terms of profitability, CRXT's ROE is -4.63%, compared to BMY's ROE of +0.39%. Regarding short-term risk, CRXT is more volatile compared to BMY. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check BMY's competition here
CRXT vs GSK Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, GSK has a market cap of 120.1B. Regarding current trading prices, CRXT is priced at $0.05, while GSK trades at $60.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas GSK's P/E ratio is 15.75. In terms of profitability, CRXT's ROE is -4.63%, compared to GSK's ROE of +0.30%. Regarding short-term risk, CRXT is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check GSK's competition here
CRXT vs SNY Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SNY has a market cap of 113.6B. Regarding current trading prices, CRXT is priced at $0.05, while SNY trades at $47.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SNY's P/E ratio is 19.48. In terms of profitability, CRXT's ROE is -4.63%, compared to SNY's ROE of +0.11%. Regarding short-term risk, CRXT is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check SNY's competition here
CRXT vs BIIB Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, BIIB has a market cap of 28.2B. Regarding current trading prices, CRXT is priced at $0.05, while BIIB trades at $192.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas BIIB's P/E ratio is 21.85. In terms of profitability, CRXT's ROE is -4.63%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, CRXT is more volatile compared to BIIB. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check BIIB's competition here
CRXT vs HZNP Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, CRXT is priced at $0.05, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas HZNP's P/E ratio is 61.86. In terms of profitability, CRXT's ROE is -4.63%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, CRXT is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check HZNP's competition here
CRXT vs GRFS Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, GRFS has a market cap of 8B. Regarding current trading prices, CRXT is priced at $0.05, while GRFS trades at $9.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas GRFS's P/E ratio is 14.46. In terms of profitability, CRXT's ROE is -4.63%, compared to GRFS's ROE of +0.07%. Regarding short-term risk, CRXT is more volatile compared to GRFS. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check GRFS's competition here
CRXT vs OGN Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, OGN has a market cap of 2.1B. Regarding current trading prices, CRXT is priced at $0.05, while OGN trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas OGN's P/E ratio is 11.25. In terms of profitability, CRXT's ROE is -4.63%, compared to OGN's ROE of +0.24%. Regarding short-term risk, CRXT is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check OGN's competition here
CRXT vs CELG-RI Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, CELG-RI has a market cap of 163.3M. Regarding current trading prices, CRXT is priced at $0.05, while CELG-RI trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, CRXT's ROE is -4.63%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, CRXT is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check CELG-RI's competition here
CRXT vs CTOR Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, CTOR has a market cap of 102.4M. Regarding current trading prices, CRXT is priced at $0.05, while CTOR trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas CTOR's P/E ratio is -3.74. In terms of profitability, CRXT's ROE is -4.63%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, CRXT is more volatile compared to CTOR. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check CTOR's competition here
CRXT vs SCLX Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SCLX has a market cap of 69.4M. Regarding current trading prices, CRXT is priced at $0.05, while SCLX trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SCLX's P/E ratio is -0.20. In terms of profitability, CRXT's ROE is -4.63%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, CRXT is more volatile compared to SCLX. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check SCLX's competition here
CRXT vs MIRA Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, MIRA has a market cap of 49.8M. Regarding current trading prices, CRXT is priced at $0.05, while MIRA trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas MIRA's P/E ratio is -0.74. In terms of profitability, CRXT's ROE is -4.63%, compared to MIRA's ROE of -9.79%. Regarding short-term risk, CRXT is more volatile compared to MIRA. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check MIRA's competition here
CRXT vs SRXH Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SRXH has a market cap of 4.3M. Regarding current trading prices, CRXT is priced at $0.05, while SRXH trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SRXH's P/E ratio is -0.75. In terms of profitability, CRXT's ROE is -4.63%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, CRXT is more volatile compared to SRXH. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check SRXH's competition here
CRXT vs SCLXW Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, CRXT is priced at $0.05, while SCLXW trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas SCLXW's P/E ratio is N/A. In terms of profitability, CRXT's ROE is -4.63%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, CRXT is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for CRXT.Check SCLXW's competition here
CRXT vs BDSIW Comparison February 2026
CRXT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CRXT stands at 0. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, CRXT is priced at $0.05, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CRXT currently has a P/E ratio of -0.02, whereas BDSIW's P/E ratio is N/A. In terms of profitability, CRXT's ROE is -4.63%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, CRXT is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for CRXT.Check BDSIW's competition here